auvelity
Generic: dextromethorphan·Brand: Auvelity
auvelity: developed by 1 company · 1 clinical trial tracked.
auvelity evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect auvelity to AXSM; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could auvelity → AXSM affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
major depressive disorder (MDD) in adultsHealthy Participants
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Axsome Therapeutics, Inc. (AXSM) major depressive disorder (MDD) in adults | Approved |
Clinical Trials (1)
An Open-label, Fixed-sequence Study to Assess the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants.
Primary endpoint: Area under concentration time curve from time 0 to infinity (AUCinf) of dextromethorphan
Interventionalopen42 enrolledStarted 2026-03Completion 2026-071 site · GermanyAstraZeneca
Frequently asked questions
Who is developing auvelity?
auvelity is being developed by Axsome Therapeutics, Inc..
How many clinical trials involve auvelity?
BioSniper tracks 1 clinical trial involving auvelity.